Zynerba Pharmaceuticals (NASDAQ: ZYNE) stock retreated on Wednesday after serious adverse events in phase 2 clinical trial of transdermal cannabidiol gel, Zygel.
Zynerba Pharmaceuticals Inc.
-(ZYNE)
XNAS:ZYNE
Cara Therapeutics stock surges after reporting Q4 earnings results
Cara Therapuetics (CARA) reports a loss of $20.7 million or $0.52 per share on revenue of $5.5 million for the fourth quarter
Earnings Preview Q4: Cara Therapeutics’ success in 2019 will depend on Korsuva trial outcomes
Cara Therapeutics (CARA) is scheduled to report its fourth quarter and full-year 2018 financial results on Tuesday, March 12, after the regular
GW Pharma stock rises after reporting earnings results for the quarter ended Dec. 31, 2018
As GW Pharmaceuticals (GWPH) moved its fiscal year beginning to January 1, 2019, the company reported financial results for the quarter ended 31
Zynerba Pharmaceuticals stock soars on receiving US patent for its CBD gel to treat Fragile X syndrome
Cannabinoid therapeutics developer Zynerba Pharmaceuticals (ZYNE) received US patent named "Treatment of Fragile X Syndrome with Cannabidiol”. Shares of Zynerba soared 15% in